• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·TLRY
Held by 2 Gurus
Share

Tilray Brands, Inc. Stocks

$ 2.81Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 317.04M

$ 2.81
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%+0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

27.05.2026 17:27

Analyst says 'don't bother' with pot stock Tilray, even after Trump's rescheduling

24.04.2026 18:14

Cannabis has been recognized as less dangerous in the US. Why did the shares of companies related to it fall?

23.04.2026 02:30

Pot stocks soar as Axios reports imminent U.S. reclassification of cannabis

19.12.2025 08:30

Despite Trump executive order, pot stocks dip as traders take profit

17.12.2025 18:35

Cannabis stocks rally as Trump 'very strongly' considering reclassifying marijuana

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tilray Brands, Inc. operates as a consumer lifestyle company primarily involved in the research, cultivation, manufacturing, and worldwide supply of medical cannabis products. Its expansive global footprint includes Canada, the United States, Europe, the Middle East, Africa, and numerous other international regions. The company's business activities are organized into four distinct segments: Beverages, Cannabis, Distribution, and Wellness. Beyond its medical cannabis offerings, Tilray Brands also provides products for adult recreational cannabis markets. The company further diversifies its portfolio by reselling and distributing pharmaceutical and wellness items, as well as producing, marketing, and selling a range of beverage and hemp-derived food products. Its offerings also extend to entertainment products. These varied products are marketed under a vast collection of brand names, featuring prominent labels such as Tilray, Aphria, Broken Coast, SweetWater Brewing, and HEXO, among many others. Tilray Brands utilizes a broad distribution network, selling its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments, and directly to consumers. The company, which was formerly known as Tilray, Inc., officially adopted the name Tilray Brands, Inc. in January 2022. Its corporate headquarters are situated in Leamington, Canada.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of TLRY is 5.58 and suggests 98.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France avoids Moody’s downgrade after a week of turmoil

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026